Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)

This study has been terminated.
Sponsor:
Collaborator:
University of Zurich
Information provided by (Responsible Party):
Biotronik, Inc.
ClinicalTrials.gov Identifier:
NCT00683696
First received: August 30, 2007
Last updated: April 17, 2014
Last verified: April 2014
  Purpose

The EchoCRT trial evaluates the effects of Cardiac Resynchronization Therapy (CRT) on mortality and morbidity of subjects with heart failure due to left ventricular systolic dysfunction, already receiving optimized HF medication, with a narrow QRS width (< 130 ms) and echocardiographic evidence of ventricular dyssynchrony.


Condition Intervention Phase
Heart Failure
Ventricular Dyssynchrony
Device: Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)

Resource links provided by NLM:


Further study details as provided by Biotronik, Inc.:

Primary Outcome Measures:
  • Composite Primary Endpoint: Number of Subjects With First Hospitalization for Worsening Heart Failure or Death [ Time Frame: From date of randomization until date of death from any cause or date of first hospitalization for worsening heart failure, whichever came first, assessed up to date of study exit, with a mean treatment duration of 1.6 years ] [ Designated as safety issue: No ]
    The primary efficacy endpoint will evaluate the effect of CRT=ON versus CRT=OFF in time to event of a combined endpoint of all-cause mortality or first hospitalization for worsening heart failure.

  • Number of Subjects That Underwent Implant Attempt Without System- or Implant-Related Complications (Complication-Free) [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    The primary safety endpoint will evaluate the complication-free rate of the Lumax HF-T CRT-D devices in the narrow QRS subject population.


Secondary Outcome Measures:
  • Rate of Worsening Heart Failure Hospitalization (Hospitalizations Per Subject-year) [ Time Frame: Study duration from randomization to study exit ] [ Designated as safety issue: No ]
    Evaluate the effects of CRT=ON compared to CRT=OFF on the rate of hospitalization for worsening heart failure (WHF).

  • NYHA Classification Change [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Evaluate the effects of CRT=ON compared to CRT=OFF in relation to the change in NYHA classification.

  • Change in Quality of Life Scores From Baseline to 6-Month Follow-up [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Evaluate the effects of CRT=ON compared to CRT=OFF in relation to the change in the Minnesota Living with Heart Failure (MLHF) Quality of Life (QOL) Questionnaire.

  • Composite Score of Death, Hospitalization for Worsening Heart Failure and Change in Quality of Life [ Time Frame: Study duration from randomization to study exit for death, 24 months for hospitalization, 6 months for QOL evaluation ] [ Designated as safety issue: No ]
    Evaluate the effects of CRT=ON compared to CRT=OFF in relation to a composite endpoint of all-cause mortality, hospitalization for worsening heart failure and change in the MLHF Quality of Life Questionnaire.

  • Number of Subjects With All-cause Mortality [ Time Frame: Study duration from randomization to study exit ] [ Designated as safety issue: No ]
    Evaluate the all-cause mortality rate between the CRT=ON compared to CRT=OFF group.


Enrollment: 1680
Study Start Date: August 2008
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CRT=ON
Cardiac Resynchronization Therapy activated.
Device: Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)
All patients will receive a commercially available BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled. Patients will be randomized to CRT=ON or CRT=OFF.
Other Name: Lumax HF-T CRT-D system
Active Comparator: CRT=OFF
Cardiac Resynchronization Therapy deactivated.
Device: Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)
All patients will receive a commercially available BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled. Patients will be randomized to CRT=ON or CRT=OFF.
Other Name: Lumax HF-T CRT-D system

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women 18 years of age or older.
  • Understand the nature of the procedure.
  • Give written informed consent.
  • Willing and able to complete all testing required by the clinical protocol.
  • Indication for an implantable cardioverter defibrillator (ICD).
  • NYHA class III-IV within the last three months prior to enrollment and at baseline (at baseline only: also Stage C according to ACC/AHA guidelines).
  • Stable optimal pharmacologic therapy for HF.
  • An ejection fraction ≤ 35% within one year prior to enrollment and confirmed on the baseline echocardiogram.
  • Increased left ventricular dimension, defined as LVEDD ≥ 55 mm.
  • Resting QRS duration < 130 ms evidenced by a historical 12-lead ECG prior to enrollment and at baseline.
  • Ventricular dyssynchrony assessed by echocardiography locally and confirmed by the echo core lab. One of the two following criteria has to be present to include the subject in the study:

    • Intra-left ventricular dyssynchrony measured by color Tissue Doppler Imaging (TDI) with an opposing wall delay of ≥ 80 ms in the 4-chamber or apical long-axis view.
    • Speckle-tracking radial strain septal-posterior wall delay ≥ 130 ms.

Exclusion Criteria:

  • Implanted pacemaker or defibrillator with >10% ventricular pacing, as demonstrated by device statistics averaged over at least the last three months prior to enrollment.
  • Women who are pregnant, lactating, or planning to become pregnant during the course of the trial.
  • Bradycardia pacing indication.
  • Surgically correctable primary valvular heart disease, i.e. aortic stenosis, torn cordae, or flail segment.
  • Coronary artery bypass graft surgery or percutaneous coronary intervention (balloon and/or stent angioplasty) within the past 3 months prior to enrollment.
  • Enzyme-positive myocardial infarction within the past 3 months prior to enrollment.
  • Angiographic evidence of coronary disease, candidates for coronary revascularization likely to undergo coronary artery bypass graft surgery or percutaneous coronary intervention in the next 3 months.
  • Irreversible brain damage from preexisting cerebral disease.
  • Reversible non-ischemic cardiomyopathy such as acute viral myocarditis.
  • Permanent second or third degree heart block.
  • Chagas disease.
  • Persistent or paroxysmal atrial fibrillation within one month prior to enrollment.
  • Expected to receive heart transplantation within six months.
  • Current inotropic therapy.
  • Acutely decompensated heart failure.
  • Contrast dye allergy and unable or unwilling to undergo pretreatment with steroids and/or diphenhydramine.
  • Life expectancy of less than six months.
  • Presence of any disease, other than the subject's cardiac disease associated with a reduced likelihood of survival for the duration of the trial, (e.g. cancer).
  • Significant renal insufficiency defined as a serum creatinine > 2.5 mg/dL (> 221 µmol/L) within the last four weeks prior to enrollment..
  • Liver failure, defined as three times the upper limit of normal for aminotransferases.
  • Participation in any other clinical trial.
  • Unable to return for follow-up visits due to distance from the clinic.
  • Do not anticipate being a resident of the area for the scheduled duration of the trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00683696

  Show 122 Study Locations
Sponsors and Collaborators
Biotronik, Inc.
University of Zurich
Investigators
Study Chair: Frank Ruschitzka, MD University of Zurich, Switzerland
Study Chair: Johannes Holzmeister, MD University of Zurich, Switzerland
Principal Investigator: William Abraham, MD Principal Investigator (USA) at The Ohio State University, OH, USA
Principal Investigator: Jagmeet Singh, MD Principal Investigator (USA) at Massachusetts General Hospital, MA, USA
  More Information

No publications provided by Biotronik, Inc.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Biotronik, Inc.
ClinicalTrials.gov Identifier: NCT00683696     History of Changes
Other Study ID Numbers: EchoCRT
Study First Received: August 30, 2007
Results First Received: March 12, 2014
Last Updated: April 17, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Biotronik, Inc.:
Cardiac Resynchronization Therapy
Heart Failure
Ventricular Dyssynchrony
Mechanical Dyssynchrony
Intraventricular Dyssynchrony
Echocardiography
Normal QRS
Heart Disease
EchoCRT

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on October 19, 2014